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Abstract
Similar biotherapeutic products (SBPs), also called biosimilars, exhibit similar biological and 
clinical properties to authorized reference products. Biosimilars, including small molecules 
like erythropoietin and complex macromolecules like monoclonal antibodies (mAbs), have 
been used extensively in disease treatment. Monoclonal antibody biosimilars have gradu-
ally become a dominant development in the global pharmaceutical industry since their 
patents or data protection have been expired or nearing expiration. Since the mAb biosimi-
lars are complex biological macromolecules with various post-translation modifications, it 
is important to evaluate whether these tiny differences significantly affect the quality. From 
a regulatory perspective, the comparability study needs to be performed to demonstrate 
that the quality, safety, and efficacy are similar to the biological reference. Based on these 
comprehensive comparative results, the indicated extrapolation might be acceptable. Post-
market surveillance is also required because of unexpected biological variation caused by 
slightly different manufacturing processes. This chapter presents the scientific and regula-
tory considerations for monoclonal antibody biosimilar products for manufactures and for 
the regulatory authorities to administrate wisely and comprehensively.
Keywords: biosimilar, monoclonal antibody, biosimilar monoclonal antibody, 
regulatory perspective, comparability study
1. Introduction
The developments of “copies” of drug products, such as generic drugs or biosimilars, have 
become the trend in the pharmaceutical markets. However, in fact, they are strikingly dif-
ferent in respect of the structure, developments, and approval requirements [1]. Unlike the 
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generic drug, which is chemically synthesized, the biosimilar is a complex molecule with 
many post-translational modifications, because it is produced from the complex living cells. 
In contrast to the generic drug, the biosimilar has immunogenic potentials. Furthermore, only 
the bioequivalence study is required for the approval of generic drug products in the regula-
tory requirements; whereas, for biosimilar products, the comparative study to demonstrate 
the biosimilarity to reference products is required [2–4]. The biosimilar is a biological product, 
which exhibits high similarities to the products already licensed in terms of quality, safety, 
and efficacy. However, the exact definition of “biosimilar” itself does not reach the consensus 
among different regulatory agencies [5]. Despite these differences among regions, the basic 
principles for biosimilars are similar [6, 7]. For harmonization on the evaluation and regula-
tion of biosimilars, the guideline on the evaluation of similar biotherapeutic products (SBPs) 
is provided by WHO Expert Committee on Biological Standardization (ECBS) [8].
Monoclonal antibodies (mAbs) are the fastest growing class of biotherapeutic products for 
treating cancer or inflammatory diseases and they can be found on the lists of the top 10 
global annual pharmaceutical revenues. As the patents or data protections have been expired 
or nearing expiration, many global pharmaceutical industries have turned toward develop-
ing similar mAb biotherapeutic products. The similar mAb biotherapeutic products, also 
called biosimilar mAbs, exhibit highly similar biological and clinical properties to the autho-
rized reference mAbs. The entry of these products into the markets could help to slow the 
increasing healthcare costs due to its affordability and accessibility. The mAb is a complex 
macromolecule with several sizes and charge variants or post-translational modifications, 
including different glycosylation profiles, or N and C terminal heterogeneities. The presence 
of differences is shown in each mAb due to the structural complexity. Although these differ-
ences are seemingly tiny, it is possible to have large impacts on the quality of final products. 
Therefore, additional guidelines that apply to mAb-derived products are demanding. In 2016, 
WHO guideline on the evaluation of biosimilar mAb products was adopted by the ECBS [9]. 
The document provides some critical considerations for manufactures as well as regulatory 
authorities for characterizing or assessing the quality of biosimilar mAb products. However, 
until now, there have been no standard analytical methods or clear specifications for defining 
the similarity in the nonclinical and clinical comparability studies. The manufactures have to 
develop their own analytical methods to prove similarity in relation to reference products, 
and these analytical methods are required to be scientifically validated [10].
The quality attributes of biosimilar mAb products might be affected by the manufacturing 
process. Manufacturers of biosimilar mAbs do not easily obtain the detailed information 
about the manufacturing process of the reference products or the usage of the active ingre-
dients [11]. In general, the amino acid sequence of the biosimilar mAbs must be identical to 
the reference mAbs; however, other characteristics, including the structure conformation, 
biological activity, or contents of impurities, might vary from products to products. To 
obtain the approval from the regulatory authorities, the comparability studies of struc-
tural and functional characterization and process-derived impurities of the biosimilar 
products and reference products are required [12]. Moreover, one mAb biotherapeutic 
product might apply to multiple indications and exert the clinical effects through differ-
ent mechanisms of action (MoA) [13]. Therefore, the comparability studies in the clinical 
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trials are also required. If any clinical differences of biosimilar mAbs compared to reference 
mAbs are found, additional evaluations must be justified to exclude any adverse effects 
[14]. However, there are many challenges for developing biosimilar mAbs, including the 
harmonization of analytical methods, development of comparative assay, and exact defini-
tions of biological activity in the clinical trials [15]. Due to the complexity of bioprocess in 
the biosimilar mAbs, very tiny differences in the manufacturing process might have large 
impacts on the quality of final products. The development process and critical concerns 
in each step are described as follows, which would be helpful for manufactures as well as 
regulatory authorities to administrate with more scientific and regulatory considerations.
2. Framework of development
From the point of product approval, the development of biosimilar mAbs may be divided into 
the pre-market and post-market stage. In the pre-market stage, to obtain the approval from 
the regulatory agencies, the biosimilar mAbs must undergo a rigorous development process 
and comparative study to demonstrate the quality, safety, and efficacy similarity to the refer-
ence mAbs. After the product approval, in order to achieve the maximal safety and quality 
of mAb biosimilar products, post-market surveillance is indispensable. The framework of 
biosimilar mAb development and critical points for considerations are shown in Figure 1 [16].
2.1. Manufacturing development
Biosimilar mAbs are developed to show similarity to reference mAbs in terms of quality, 
safety, and efficacy. The manufacturing development of biosimilar mAb products might be 
different from that of reference mAbs, because some detailed information of the manufactur-
ing process of reference mAb is not accessible by the manufactures [11]. In order to reduce 
any unnecessary clinical safety and efficacy effects, the manufacturing process should be 
optimized to minimize the differences between biosimilar mAbs and reference mAbs. It is 
advisable that the manufacturing process of biosimilar mAbs should be as similar as pos-
sible to that of reference mAbs and the manufactures should understand each manufacturing 
process. If any differences in the manufacturing process are found, the potential impacts of 
changing elements on the product quality, safety, and efficacy should be evaluated and justi-
fied [17].
Figure 1. Framework development and critical points for considerations of biosimilar mAbs.
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2.1.1. Expression system
Choice of suitable expression system is one of the critical points for the manufacturing pro-
cess. According to the WHO guidelines, a different expression system is allowed for the 
production of biosimilar mAb products [8, 9]. Although the primary structure (amino acid 
sequence) is not affected by different host cell lines, the protein modifications, including 
N-terminal truncation, C-terminal truncation, or post-translation modification, and process-
derived impurities like residual host DNAs or residual host proteins might be affected. These 
changes might indirectly affect the biological effects in the clinical consequences. In most 
cases, when different host cell types are used, different glycosylation profiles might be found 
[18]. For example, the mAb products produced from mouse cell lines, like NS0 or SP2/0 cells, 
have alpha-1,3-gal in their carbohydrate structure. However, there is no production of such 
structure in the human cell lines, because these cell lines lack the necessary enzyme to synthe-
size the alpha-1,3-gal antigens [19]. Moreover, the immune response against this“special” gly-
cosylation structure would be triggered in the human body, which might lead to the adverse 
clinical effects. This situation could be avoided by using Chinese hamster ovary (CHO) cells 
[20]. Therefore, to minimize the differences between biosimilar products and reference prod-
ucts, the choice of the expression system for the mAb biosimilar products should be carefully 
considered. In general, it is advisable for the manufactures to choose the same host cell type 
as that of reference mAbs to minimize the possible impact on the clinical efficacy and safety 
of the products when developing mAb biosimilars.
2.1.2. Impurity
Product impurity is inevitable in the manufacturing process. Impurities, the components 
which are not desired in the drug substance or drug products, might trigger some safety 
concerns [21]. To ensure the safety of products, the differences of impurity profiles between 
the biosimilar mAbs and reference mAbs need to be evaluated. For mAb products, the test-
ing of impurity includes the analysis of residual host DNA, residual protein A, or monomer 
contents in the products. If any differences between biosimilar mAbs and reference mAbs are 
significantly observed, additional evaluation of the impurity-derived impacts on the product 
safety and efficacy is required [8, 12, 22].
2.1.3. Specification
The specification (acceptance criteria) needs to be considered in the manufacturing process. 
The specification of biosimilar mAbs is not actually the same as that of reference mAbs. 
Sufficient batches of biosimilar mAb products are needed for the collaborative study. The 
setting of specification of biosimilar mAbs is based on the manufacturing experiences or 
comparative results of the collaborative study on biosimilar mAbs and reference mAbs. In 
general, the limit setting of biosimilar mAbs should not be wider than the range of variability 
of reference mAbs. If the acceptance criteria of biosimilar mAbs are significantly out of the 
acceptable range of reference mAbs, additional evidence to confirm the safety of products is 
needed [21, 23].
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2.2. Comparability exercise
From the regulatory requirements, the comparability exercise of biosimilar mAbs and refer-
ence mAbs must be needed. According to ICH Q5E, the comparability study should prove 
that the proposed product is highly similar to the reference product before and after the 
manufacturing process changes [24]. The comparability data of quality attributes might be 
the foundation for reducing the requirements of non-clinical and clinical studies. When con-
sidering that batch variabilities might affect the results of comparability exercise, products 
from different batches should be evaluated. What is more, the analytical methods in the com-
parability exercise should be sensitive to detect the potential differences between biosimilar 
mAbs and reference mAbs and the parameter ranges for each analytical methods need to be 
determined by an appropriate statistical analysis [8, 9, 25].
To obtain representative data from the comparability exercise, the choice of a suitable refer-
ence mAb is important. Comprehensive information of reference mAbs could be the founda-
tion for the establishment of quality, safety, and efficacy profiles, to which are the biosimilar 
mAbs compared. Head-to-head comparisons are performed to demonstrate high level of 
biosimilarity between the biosimilar mAbs and reference mAbs in the comparability exercise 
[26]. Following considerations are provided for the choice of suitable reference mAb biothera-
peutic products [8, 12, 22].
• Whether the reference products have already been authorized based on the integrated set 
of quality, safety, and efficacy data.
• Whether the drug substance, active ingredient, and the biological function of biosimilar 
mAbs are similar to those of reference mAbs.
• Whether the dosage form and route of administration of biosimilar mAbs are identical to 
that of reference mAbs.
• Whether the same reference products are used throughout the comparative quality, safety, 
and efficacy studies.
2.2.1. Quality assessment
The quality comparative studies are conducted by the state-of-art analytical techniques 
and appropriate analytical methods. The analytical methods should be sensitive enough to 
detect any differences between biosimilar mAbs and reference mAbs. For the development 
of analytical methods, the information of the analytical limitations, like specificity in each 
analytical technique should be known by the manufactures. The characteristics including 
physicochemical, biological, and other related properties (e.g., impurities, finished products, 
and specification) are analyzed by the head-to-head comparative studies [27–30]. For mAb 
analysis, the common characteristics and analytical methods to ensure product quality are 
provided in Table 1, and these analytical items could also be applied to the comparative study 
of biosimilar mAbs and reference mAbs [5].
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2.2.1.1. Physicochemical properties
The characterization of physicochemical properties for biosimilar mAbs is required, due to 
the inherent complexity of mAb products. The monoclonal antibody is a macromolecule with 
size and charge variants and different post-translational modifications. The structural het-
erogeneity should be analyzed by the state-of art techniques. The physicochemical testing 
should include the determination of the primary structure (e.g., amino acid sequence), higher 
order structure (e.g., disulfide bond bridges, free thiol functional group, and secondary or 
tertiary structures), and some physicochemical properties (e.g., charge variants, site-specific 
glycosylation patterns, or glycan profiles) [12].
The analysis of the primary structure is the determination of the amino acid sequence of prod-
ucts. In general, the primary structure of mAb SBPs should be identical to that of reference 
Characteristics Items Analytical methods
Primary structure Intact mass analysis Mass spectrometric analysis
Peptide mapping Enzyme digestion and HPLC
N-terminal sequence Edman degradation
C-terminal sequence Peptide mapping and intact molecular mass 
analysis
Disulfide bond bridge analysis Peptide mapping under nonreduced condition
Glycosylation site Peptide mapping with mass spectrometric 
analysis
Higher order structure Structure analysis Circular dichroism
Post-translational modification Glycan profiles Enzyme digestion and mass spectrometric 
analysis
Sialic acid content HPAEC-PAD
Heterogeneity Isoforms cIEF
Immunological activity Binding affinity Enzyme immunoassay
Biological activity Potency Cell-based assay
Purity/impurity Product-related impurity HPLC
Process-related impurity Host cell protein ELISA
Residual DNA PCR
Residual protein A ELISA
Endotoxin LAL
HPAEC-PAD: high performance anion exchange chromatography with pulsed amperometric detection; HPLC: high-
performance liquid chromatography; cIEF: capillary isoelectric focusing; ELISA: enzyme-linked immunosorbent assay; 
PCR: polymerase chain reaction; LAL: limulus amebocyte lysate.
Table 1. Analytical items and analytical methods for the analysis of mAb characterization.
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mAbs, except for the structural heterogeneity in the N-terminus or C-terminus. Peptide 
mapping is a common analytical method to identify or quantify the abundance of heteroge-
neous forms. For higher order structures, the conformation stability is critical for functional 
properties. For example, the differences in intra-disulfide bridges could directly affect the 
IgG2 affinities in mAb products [31]. The commonly analytical techniques used in the test-
ing include hydrogen-deuterium exchange mass spectrometry (H/DX-MS), circular dichro-
ism (CD), and two-dimensional nuclear magnetic resonance (2D-NMR). H/DX-MS is used 
to identify the rigid or flexible domain of the protein structure in the formulation conditions, 
CD is used to assess the content of secondary structure, and 2D-NMR is used to analyze the 
integrity of protein structure [32]. In some situations, a combination of two or more analytical 
techniques, like capillary electrophoresis coupled with mass spectrometry, might be powerful 
in characterizing the physicochemical properties [33].
The comparability exercise on the post-translational modification of biosimilar mAbs and 
reference mAbs is required in the physicochemical analysis. The comparative glycan analysis 
includes the N-glycan analysis, site-specific glycosylation patterns, or overall glycan profile [34]. 
Given that small differences in glycan profiles could cause unexpectedly immunogenic con-
sequences, additional data to support the product safety are required. Moreover, the high 
heterogeneity of the active ingredients increases the complexity of the structure or other 
physicochemical properties, which caused it difficult to analyze the different variants in one 
analytical method. To solve these problems, the combination of the different analytical meth-
ods, like ion exchange chromatography, isoelectric focusing, and capillary electrophoresis, 
is developed. However, the analytical techniques of physicochemical analytical methods are 
restricted to its detection limits, so that some higher order structure of the molecule or slight 
difference of mAb SBPs and reference mAbs are not easily detected by the physicochemi-
cal analysis. To complement the detection limits of physicochemical analysis, the biological 
analysis is performed to determine whether the heterogeneous variants have impact on the 
product safety.
2.2.1.2. Biological activity properties
Biological activity, also called potency, is defined as the product’s specific ability to achieve 
the intended biological effects. It is an important parameter for characterizing the product 
quality and batch analysis. Biological assay is the quantitative measure of the biological activ-
ity and reflects the mechanism of action of the functional protein. The data obtained from the 
biological assays could connect to the clinical activity. Additionally, the biological assay com-
plements the physicochemical analysis to confirm the structural integrity of the molecules. 
The analytical method for biological activity should be specific and sensitive enough to detect 
slight differences in batch analysis or comparative study. The biological activity should be 
determined by calibrating against international or national standards, and the results could 
be expressed in international units (IU) or units (U) of activity [8, 9, 12].
The mechanism of the action of mAbs varies ranging from simple antigen binding, which 
alone affects the clinical response, to antigen binding with one or more immunological effects, 
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which combines to present an overall clinical response. For example, infliximab, which is a 
chimeric monoclonal antibody specific for tumor necrosis factor alpha (TNF-α), achieves clin-
ical efficacy in rheumatoid arthritis through the mechanism of antigen binding [35]. However, 
rituximab, specific for binding to CD20, requires the Fc function for its clinical efficacy in all 
the clinical indications [36]. The mAb consists of two major functional domains, including 
Fab and Fc fragments. For characterizing biological activity properties, the assay should be 
designed for analyzing binding affinity and functional activities of these two regions. If it can 
be shown that the clinical effects are only affected through antigen binding, the ligand bind-
ing assays could estimate biological activity. Given that the Fc part of mAb might mediate 
the immunobiological effects, the relevant, validated potency assay for the determination of 
other immunobiological effects other than just potency should be developed. In this regard, 
the choice of appropriate cell-based assays to determine the potency should be considered.
2.2.1.3. Immunological properties (immunogenicity)
Immunogenicity is the ability/capability of molecules to elicit the immune response against 
external substances. The immune response against the mAb biotherapeutic products is affected 
by many factors, including the drug substances, excipients, process derived impurities, route of 
administration, dosing regimen, or other related factors [12]. For the analysis of immunological 
properties, the binding specificity, binding affinity, and binding kinetics all need to be analyzed 
by scientifically analytical methods, such as surface plasmon response, microcalorimetry, or 
classical Scatchard analysis. Moreover, the Fab-associated functions (neutralization of soluble 
antigens or receptor activation/blockade) and the Fc-associated functions (antibody-dependent 
cell cytotoxicity, complement-dependent cell cytotoxicity, apoptosis, or complement activa-
tion) should also be analyzed using appropriate analytical methods [8, 9]. These analytical 
methods should be sensitive enough to detect the difference between biosimilar products and 
reference products.
2.2.2. Nonclinical study
Nonclinical study encompasses the pharmacological/toxicological assessments of biosimilar 
products. By referring to the results from the physicochemical and biological characterization 
studies, the nonclinical study program is designed to detect potential impacts on safety and 
efficacy of biosimilar products. Nonclinical studies can be divided into in vitro studies and in vivo 
studies. In vitro studies should be conducted first, since the results from in vitro studies could 
make a decision to the extent of what in vivo studies are required. The considerations for in vitro 
studies and in vivo studies are discussed as follows [9, 37, 38].
2.2.2.1. In vitro study
To assess the difference of biological activity between a biosimilar product and a reference 
product, in vitro studies should be performed. Compared to animal studies, an in vitro assay 
is more specific and sensitive to detect differences between the biosimilar products and 
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reference products [39]. For establishments of in vitro studies of biosimilar mAbs, the follow-
ing points should be taken into account.
• The assay needs to be scientifically valid and has the ability to detect biological differences 
between biosimilar mAbs and reference mAbs, not just the response of biosimilar mAbs.
• An appropriate number of batches of reference mAbs and biosimilar mAbs are required, 
given that the results will be affected by variabilities with different batches.
• The number of tests should be adjusted sufficiently to make the meaningful conclusions 
that biosimilar mAbs demonstrate similarity in biological activity to reference mAbs.
• The data from in vitro studies should cover the pharmacological/toxicological assessments, 
which could be a reference supportive for the clinical design.
For nonclinical in vitro program of biosimilar mAbs, the biological analysis of Fab and Fc frag-
ments should be included. Following table summarizes the analytical items and analytical 
methods in the nonclinical in vitro program of biosimilar mAbs [9] (Table 2).
2.2.2.2. In vivo study
In vivo study is designed to provide more information on “unexpected” pharmacological/
toxicological activities relevant to the clinical application. Such studies could be comparative 
in nature and can detect the differences between biosimilar products and reference products. 
However, when the necessary information has already obtained from in vitro studies, in vivo 
studies are not required. Following points are provided for the determination of the need for 
in vivo studies [40].
Item Method
Fab-associated Fc-associated
Binding studies • Target antigen binding • Binding to Fc receptors 
(FcγRI, FcγRII, FcγRIII, 
and FcRn)
• Binding to complement 
(C1q)
• ELISA
• Surface plasmon 
resonance (SPR)
• Flow cytometry
Biological activities/
functional assay
• Neutralization of soluble 
ligand
• Receptor activation
• Receptor blockade
• Antibody-dependent cell 
cytotoxicity (ADCC)
• Complement-dependent 
cytotoxicity (CDC)
• Complement activation
• Apoptosis
• Cell-based assay
Table 2. Analytical items and analytical methods of in vitro nonclinical study of biosimilar mAbs.
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• The data of biological activity or pharmacodynamics could be available from the biological 
assays in the part of the quality assessment. If these data are sufficiently reliable to reflect 
the relevant clinical situation, in vivo studies would not be necessary. Accordingly, if the 
data are not fully elucidated by in vitro assay, in vivo assay is required.
• The monoclonal antibodies might mediate the unprecedented effects that cannot be fully 
characterized by an in vitro assay. In this situation, in vivo studies are required to provide 
complementary information.
If in vivo studies are required, the following points are needed for consideration.
• Choice of animal species and the relevant models (in-breed animals, transgenic animals, or 
transplant models) for the assay.
• If there are no appropriate animal models for in vivo assay, the manufacture needs to evalu-
ate any potential risks by the data from in vitro assay, when proceeding to the clinical trials.
• Some factors need to be considered, when considering whether the additional in vivo assays 
should be performed
1. Presence of potential quality attributes in biosimilar mAb products, which have not 
been detected in the reference mAbs.
2. The relevant quantitative differences in the comparative measurements between bio-
similar mAbs and reference mAbs.
3. The difference formulation is used. For example, the excipient is not commonly used 
in the mAbs.
2.2.3. Clinical study
Clinical study for biosimilar mAb aims to confirm the safety and efficacy issues from the clini-
cal view. For the design in the biosimilar mAb clinical trial program, the natural characteristics, 
intended indication, and duration should be taken into consideration. In fact, the design of most 
comparative clinical study is based on the clinical experiences, which had already been acquired 
from the reference mAb. It is advisable to use the finished products for clinical studies, so as to 
obtain pivotal data for marketing authorization from the regulatory authorities. The clinical com-
parability exercise is performed in a step-wise procedure, and usually begins with the clinical 
pharmacodynamics (PD) and pharmacokinetic (PK) studies, followed by the comparative clini-
cal safety and efficacy study in a selected indication. Due to the clinical experiences of reference 
products, some steps of the biosimilar mAb clinical trial are not necessary, such that the phase 2 
clinical trial (dose finding study) is not required, when the dosage used in the biosimilar mAb 
administration regimen is the same as that used in the reference mAb [11, 41]. Therefore, compared 
to the development of reference mAbs, the development of biosimilar mAbs needs less time.
The extent and number of clinical trials of biosimilar mAbs compared to reference mAbs 
could be affected by the following factors [42]:
• The intrinsic complexity (structural and biological properties) of biosimilar mAbs.
• The limitations of studies in the nonclinical comparative structural and biological study.
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• The complexity of mechanisms of action of biosimilar mAbs.
• The degree of uncertainty of biosimilar mAbs in efficacy and safety issues.
• The clinical experiences obtained from the reference mAbs.
Although the clinical trial design of biosimilar mAbs followed the same guideline as other 
similar biotherapeutic products, additional considerations are required. The indication 
extrapolation is one of the important considerations for biosimilar mAb clinical studies. To 
provide justification for indication extrapolation, the equivalence clinical trial is preferred 
over the noninferiority trial. An equivalence trial is demonstrated to confirm that the bio-
similar mAb is clinically similar to the reference mAb. This demonstration could provide the 
efficacy and safety data of biosimilar mAbs that could be a strong rationale for extrapolation 
to other indications of reference mAbs. In an equivalence trail, it is advisable to choose the 
sensitive and well-established study models regarding to the study population and study 
endpoints, given that assay with sensitivity should have the ability to detect differences 
between the biosimilar mAbs and reference mAbs, even if only tiny difference exists. In 
order to minimize the impacts on inter-patients variability, the selected study population 
for the clinical trial should be homogeneous and increase the likelihood that the observed 
clinical effects are caused by the difference between biosimilar mAbs and reference mAbs. In 
general, patients without previous treatments are good study models, because the observed 
clinical effects could exclude the interference effects of other medications [42–45].
2.3. Post-market surveillance
Post-market surveillance is an important process in achieving a maximum safety and effective-
ness of mAb biosimilars. It is a long-term monitoring to detect or assess any product-derived 
adverse effects. Some of these effects may not easily be detected during the preapproval 
clinical testing, because the narrow population is tested in the trials. In addition, due to the 
changes of material sources, facility or regulatory requirements, the manufacturing process of 
biosimilar mAb products might change. In some situations, the profiles of post-translational 
modification alter during the product life cycle, which might directly or indirectly affect 
the product safety or effectiveness. For example, Remicade (infliximab) has gone through 
over 35 changes since product approval in 1999, but no any adverse effects were reported in 
the clinical usage [46]. However, the change of glycosylation profiles of Rituxan (anti-CD20 
antibody) has been reported from batches to batches, which directly or indirectly affects the 
product immunogenicity [47]. Therefore, continuous post-marketing surveillance of products 
is required so as to make prompt prevention for adverse effects.
The following considerations are indicated when designing the program of post-marketing 
safety monitoring.
• Whether to identify low-frequency adverse reactions associated with biosimilar mAb prod-
ucts (not easy to identify the pre-marketing stages).
• Whether to identify some high-risk groups.
• Whether to discern that the adverse effects are caused by the biosimilar mAb product, not 
by the reference mAb.
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• Whether safety monitoring is continuous.
• Whether the risk or hazard prevention measures could be initiated promptly.
3. Indication extrapolation
The comparative study data of biosimilar products and reference products in one indica-
tion could extrapolate to other indications, in which reference products originally have 
been approved. Extrapolation is an important process for biosimilar developments, because 
it could reduce/eliminate the need for duplicative clinical studies [48]. The recommended 
principles of indication extrapolation of biosimilar mAbs could refer to the WHO guidance 
document about the evaluation of SBP. In general, to make indication extrapolation possible, 
the following points are needed.
• The mechanism of action of a biosimilar product and a reference product is the same.
• The clinical test is sensitive enough to detect the potential differences between biosimilar 
products and reference products.
• The safety and immunogenicity data of biosimilar products in one indication are well char-
acterized and there are no additional safety concerns when extrapolating these data to 
other indications.
• Additional convincing data must be provided to support extrapolation to other conditions 
of use.
For biosimilar mAbs, some points should be considered. Unlike other biologics, monoclo-
nal antibodies have two functional domain—Fab and Fc domains. Each domain might exert 
their clinical effects through different mechanisms, including the receptor blockage, signal-
ing induction or down-regulation, receptor down-regulation, and cell cytotoxicity (ADCC, 
CDC, or apoptosis). One monoclonal antibody might exert the clinical effects through one 
or a combination of these mechanisms in different indications. For example, infliximab 
does not require Fc function in rheumatologic and psoriatic indications; however, it exerts 
the clinical effects through the Fc domain in inflammatory bowel disease (IBD) [49]. When 
the mechanism of action (MoA) of biosimilar products is different to that of reference prod-
ucts, the indication extrapolation could be challenging. In some cases, the drug dosage 
of one product might not be the same between different indications; therefore, different 
dosages are needed to be tested. Moreover, a reference mAb might hold different types of 
indications. For example, rituximab (anti-CD20 mAb) is authorized for the treatment of 
both inflammatory diseases and cancer [50]. Since the pharmacokinetic data are different 
between these two diseases, it is inappropriate for biosimilar products to extrapolate.
4. Conclusions
With the trend of global pharmaceutical developments, the era of biosimilar mAbs has 
begun. It is clear that the entry of biosimilar products to the markets would bring benefits 
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for science and healthcare. With regard to biosimilar mAb manufactures, the reduction of 
production costs, choice of suitable cells, and control parameters setting to avoid product 
heterogeneity are important in the manufacturing process. From the regulatory perspec-
tive, the abbreviated development program is adopted in the biosimilar mAb products. 
Besides the data, which support the quality, safety, and efficacy of products, the com-
parative data to demonstrate the similarity between the biosimilar mAb product and the 
reference product needed to be submitted. Considering the impacts of batch variability 
on comparative results, different lots of products should be included in the in-depth com-
parative analysis. The integrated set of data from the comparative results would be the 
foundation for biosimilar development and the determination of the need for the extents 
that animal studies and clinical trials should be performed. For the clinical studies, it is 
advisable to choose one condition of use that would be sensitive to detect the clinical 
meaningful differences between the proposed biosimilar mAb and the reference mAb. 
However, some product-derived adverse effects might not be easily detected during the 
preapproval clinical testing. Based on the regulatory guideline requirements, pharmaco-
vigilance and risk management plan for biosimilar mAbs should be submitted to regula-
tory authorities for dossier review. The risk management plans, which are proposed by 
the manufactures, should include the detailed information on the safety and risk concerns. 
However, challenges remain with an abbreviated pathway for biosimilar mAbs, including 
the lack of detailed information and acceptance criteria for biosimilarity demonstration. 
In order to promote the global development and achieve the maximal safety of biosimilar 
mAbs, it is expected that manufacturers should cooperate with regulatory authorities to 
fight against current challenges with more detailed scientific considerations from a regula-
tory perspective.
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